Galectin-3 and soluble RAGE as new biomarkers of post-infarction cardiac remodeling

被引:5
|
作者
Redondo, Alfredo [1 ,2 ]
Paradela-Dobarro, Beatriz [3 ,4 ]
Moscoso, Isabel [3 ,4 ]
Moure-Alvarez, Maria [1 ,2 ]
Cebro-Marquez, Maria [3 ]
Gonzalez-Juanatey, Jose Ramon [1 ,2 ,3 ,4 ]
Garcia-Seara, Javier [1 ,2 ,3 ,4 ]
Alvarez, Ezequiel [4 ,5 ]
机构
[1] Complexo Hosp Univ Santiago de Compostela CHUS, Serv Cardiol, SERGAS, Travesia Choupana S-N, Santiago De Compostela 15706, A Coruna, Spain
[2] Complexo Hosp Univ Santiago de Compostela CHUS, Unidad Hemodinam, SERGAS, Travesia Choupana S-N, Santiago De Compostela 15706, A Coruna, Spain
[3] Complexo Hosp Univ Santiago de Compostela CHUS, Unidad Hemodinam, Inst Invest Sanitaria Santiago de Compostela IDIS, Travesia Choupana S-N, Santiago De Compostela 15706, A Coruna, Spain
[4] CIBERCV, Madrid, Spain
[5] Complexo Hosp Univ Santiago de Compostela CHUS, Lab 6, Inst Invest Sanitaria Santiago de Compostela IDIS, SERGAS, Edif Consultas Externas,Planta 2, Santiago De Compostela 15706, A Coruna, Spain
来源
JOURNAL OF MOLECULAR MEDICINE-JMM | 2021年 / 99卷 / 07期
关键词
Acute myocardial infarction with ST-segment elevation; Post-infarction remodeling; Galectin-3; Soluble RAGE; Biomarkers; GLYCATION END-PRODUCTS; MYOCARDIAL-INFARCTION; ATRIAL-FIBRILLATION; SERUM GALECTIN-3; HEART-FAILURE; RECEPTOR; FIBROSIS; EXPRESSION; S100B; ASSOCIATION;
D O I
10.1007/s00109-021-02054-6
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
Post-infarction remodeling is a clinical problem with no curative treatment. Our objective was to search for new biomarkers of cardiac remodeling that have clinical value after ST-segment elevation myocardial infarction (STEMI). This pilot study enrolled 67 consecutive patients with de novo STEMI who underwent revascularization by primary angioplasty. Echocardiography studies of cardiac function were completed during the first 48 h post-STEMI and after 6 months of follow-up. Galectin-3 and soluble receptor for advanced glycation end products (sRAGE) were tested in the peripheral venous blood during the 24 h post-infarction. Cardiac remodeling was defined as changes >= 15% in the left ventricular end-systolic volume (LVESV) or > 10% in the left atrial area (LAA). An inverse association was found between galectin-3 (r(s) = - 0.296; p < 0.001) and sRAGE (r(s) = - 0.327; p < 0.001) levels and the basal left ventricle ejection fraction (LVEF). However, only galectin-3 was directly associated with the increase in LVESV (r(s) = 0.389; p = 0.007) and LVEDV (r(s) = 0.314; p = 0.031) during the follow-up. sRAGE was inversely related to the change in LAA (r(s) = - 0.320; p = 0.032). These data are consistent with galectin-3, but not sRAGE levels, as a predictor of left ventricle remodeling (OR 1.036, 95% CI 1.002-1.071; p = 0.039). Galectin-3 and sRAGE levels that were measured during hospitalization are inversely related to basal LVEF after a STEMI. Galectin-3 levels are a predictor of adverse post-STEMI LV remodeling, whereas sRAGE levels exhibited an inverse relationship with left atrial remodeling. Key messages Post-infarction remodeling is a clinical problem with no curative treatment. New biomarkers for remodeling after acute myocardial infarction were explored. Early post-STEMI galectin-3 and soluble RAGE are inversely related with left ventricle function. Galectin-3 levels were predictors of adverse post-STEMI left ventricle remodeling. Soluble RAGE levels were associated with left atrial remodeling.
引用
收藏
页码:943 / 953
页数:11
相关论文
共 50 条
  • [21] Protective effect of Galectin-3 inhibitor against cardiac remodelling in an isoprenaline-induced myocardial infarction in type 2 diabetes
    Mahmoud, Manal Moustafa
    Hassan, Mai Mohammed
    Elsayed, Hany El-Sebaee
    Fares, Amal E.
    Saber, Mona M.
    Rashed, Laila Ahmed
    Abdelwahed, Omaima Mohammed
    ARCHIVES OF PHYSIOLOGY AND BIOCHEMISTRY, 2025, 131 (01) : 94 - 107
  • [22] Galectin-3 Levels and Outcomes After Myocardial Infarction A Population-Based Study
    Asleh, Rabea
    Enriquez-Sarano, Maurice
    Jaffe, Allan S.
    Manemann, Sheila M.
    Weston, Susan A.
    Jiang, Ruoxiang
    Roger, Veronique L.
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2019, 73 (18) : 2286 - 2295
  • [23] Galectin-3 and aldosterone as potential tandem biomarkers in pulmonary arterial hypertension
    Calvier, Laurent
    Legchenko, Ekaterina
    Grimm, Lena
    Sallmon, Hannes
    Hatch, Adam
    Plouffe, Brian D.
    Schroeder, Christoph
    Bauersachs, Johann
    Murthy, Shashi K.
    Hansmann, Georg
    HEART, 2016, 102 (05) : 390 - 396
  • [24] Involvement of galectin-3 in cadmium-induced cardiac toxicity
    Yazihan, Nuray
    Kocak, Mehtap Kacar
    Akcil, Ethem
    Erdem, Onur
    Sayal, Ahmet
    Guven, Cengiz
    Akyurek, Nalan
    ANADOLU KARDIYOLOJI DERGISI-THE ANATOLIAN JOURNAL OF CARDIOLOGY, 2011, 11 (06): : 479 - 484
  • [25] Engineering Human Cardiac Muscle Patch Constructs for Prevention of Post-infarction LV Remodeling
    Wang, Lu
    Serpooshan, Vahid
    Zhang, Jianyi
    FRONTIERS IN CARDIOVASCULAR MEDICINE, 2021, 8
  • [26] Galectin-3 Is Associated with Cardiac Fibrosis and an Increased Risk of Sudden Death
    Sherpa, Mingma D.
    Sonkawade, Swati D.
    Jonnala, Vinesh
    Pokharel, Saraswati
    Khazaeli, Mahyar
    Yatsynovich, Yan
    Kalot, Mohamad A.
    Weil, Brian R.
    Canty Jr, John M.
    Sharma, Umesh C.
    CELLS, 2023, 12 (09)
  • [27] Galectin-3 predicts response and outcomes after cardiac resynchronization therapy
    Andre, Clementine
    Piver, Eric
    Perault, Romain
    Bisson, Arnaud
    Pucheux, Julien
    Vermes, Emmanuelle
    Pierre, Bertrand
    Fauchier, Laurent
    Babuty, Dominique
    Clementy, Nicolas
    JOURNAL OF TRANSLATIONAL MEDICINE, 2018, 16
  • [28] ST2 and galectin-3 as novel biomarkers for the prediction of future cardiovascular disease risk in preeclampsia
    Atakul, Nil
    Atamer, Yildiz
    Selek, Sahabettin
    Kilic, Berna
    Koktasoglu, Fatmanur
    JOURNAL OF OBSTETRICS AND GYNAECOLOGY, 2022, 42 (05) : 1023 - 1029
  • [29] Galectin-3 is an independent marker for ventricular remodeling and mortality in patients with chronic heart failure
    Lok, Dirk J.
    Lok, Sjoukje I.
    de la Porte, Pieta W. Bruggink-Andre
    Badings, Erik
    Lipsic, Eric
    van Wijngaarden, Jan
    de Boer, Rudolf A.
    van Veldhuisen, Dirk J.
    van der Meer, Peter
    CLINICAL RESEARCH IN CARDIOLOGY, 2013, 102 (02) : 103 - 110
  • [30] Galectin-3 is expressed in the myocardium very early post-myocardial infarction
    Hashmi, Satwat
    Al-Salam, Suhail
    CARDIOVASCULAR PATHOLOGY, 2015, 24 (04) : 213 - 223